Computational Screening for Active Compounds Targeting Protein Sequences: Methodology and Experimental Validation
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The three-dimensional (3D) structures of most protein targets have not been determined so far, with many of them not even having a known ligand, a truly general method to predict ligand-protein interactions in the absence of three-dimensional information would be of great potential value in drug discovery. Using the support vector machine (SVM) approach, we constructed a model for predicting ligand-protein interaction based only on the primary sequence of proteins and the structural features of small molecules. The model, trained by using 15,000 ligand-protein interactions between 626 proteins and over 10,000 active compounds, was successfully used in discovering nine novel active compounds for four pharmacologically important targets (i.e., GPR40, SIRT1, p38, and GSK-3β). To our knowledge, this is the first example of a successful sequence-based virtual screening campaign, demonstrating that our approach has the potential to discover, with a single model, active ligands for any protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
p38MAPK: stress responses from molecular mechanisms to therapeutics
Coulthard, L. R., White, D. E., Jones, D. L., McDermott, M. F., & Burchill, S. A. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.06.005 · Cited by 691
The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer
Yong, H.-Y., Koh, M.-S., & Moon, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903321490 · Cited by 422
Cited by
Artificial intelligence in drug discovery and development
Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.010 · Cited by 1,695
Lee, I., Keum, J., & Nam, H. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1007129 · Cited by 675
Chen, L., Tan, X., Wang, D., Zhong, F., Liu, X., Yang, T., Luo, X., Chen, K., Jiang, H., & Zheng, M. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa524 · Cited by 607
Self-citationOu-Yang, S.-S., Lu, J.-Y., Kong, X.-Q., Liang, Z.-J., Luo, C., & Jiang, H. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.109 · Cited by 352
Self-citationArtificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development
Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N. M., Das, D., Bidarolli, M., & Sony, H. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032026 · Cited by 347
“…SVM method, incorporating training on about 15,000 protein–ligand interactions, that have been advanced grounded upon primary protein sequences as well as structural features of small compounds to identify nine fresh molecules and their interaction with four vital targets have been documented [55].”
He, S., Leanse, L. G., & Feng, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113922 · Cited by 141
Metadata
- Authors
- Wang, F., Liu, D., Wang, H., Luo, C., Zheng, M., Liu, H., Zhu, W., Luo, X., Zhang, J., & Jiang, H.
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-10-11
- Volume
- 51
- Issue
- 11
- Pages
- 2821-2828
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W2047070075
- Cited by
- 80
- References
- 4
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.